18th July 2015 - New research
A dry powder inhaler has been found to be a viable means of administering L-dopa. Because
of its rapid onset of action, pulmonary administration of L-dopa is a possible alternative to
the oral administration of L-dopa in Parkinson's Disease patients in an off period. Its means
of administration could enable a very quick therapeutic effect.
Researchers studied the ability of people with
Parkinson's Disease to operate a dry powder inhaler
(DPI) correctly during an off period. They used an
instrumented test inhaler with three different resistances
to air flow. The volumes inhaled varied from 1.2 litres
to 3.5 litres. Total inhalation time and the time to peak
inspiratory flow rate both decreased with decreasing
inhaler resistance. Nearly all of the patients could hold
their breath for at least five seconds after inhalation and
most of them could extend this time to ten seconds.
The data from this study indicate that patients with Parkinson's disease will be able to use a
dry powder inhaler during an off period and they provide an adequate starting point for the
development of an L-dopa powder inhaler.
An L-dopa inhaler using L-dopa in liquid form instead of a dry form, that takes only 10
minutes to start having effect, is already undergoing clinical trials in Parkinson's Disease.
For
more information go to :
http://www.viartis.net/parkinsons.disease/news/150625.htm
Reference : PLoS One [2015] 10 (7) : e0132714 (M.Luinstra, A.W.Rutgers, H.Dijkstra, F.
Grasmeijer, P.Hagedoorn, J.M.Vogelzang, H.W.Frijlink, A.H.de Boer)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/26173114
http://www.viartis.net/parkinsons.disease/news/150718.pdf
mail@viartis.net
©2015 Viartis
No comments:
Post a Comment